Travere Therapeutics, Inc. (TVTX) News
Track canonical SquawkNews coverage tagged to TVTX, Travere Therapeutics, Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 7 indexed stories across 6 publication days and is ordered by the same first-publication timeline used by LiveCast.
M
Travere Therapeutics names Bradley Campbell CEO effective Dec. 1
Travere Therapeutics appointed Bradley Campbell as president and chief executive officer, effective Dec. 1, as Eric Dube steps down to focus on health and family.
EQUITY | Sep 21, 2026, 08:25 PM UTC
L
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Travere Therapeutics, Inc. NASDAQ:TVTX
NEWS | Sep 11, 2026, 09:03 PM UTC
H
Wynn Resorts Posts Upbeat Q2 Earnings, Joins Bloomin' Brands, Shopify, Owens Corning And Other Big Stocks Moving Higher On Wednesday
U.S. stocks were higher, with the Dow Jones index gaining around 500 points on Wednesday. Shares of Wynn Resorts Ltd (NASDAQ: WYNN ) rose sharply after the company reported better-than- expected quarterly financial resul
EARNINGS | Aug 05, 2026, 02:01 PM UTC
L
TVTX Sees Robust FILSPARI Demand
TVTX reports strong FILSPARI sales growth
EARNINGS | Aug 04, 2026, 08:14 PM UTC
M
TVTX: Guggenheim Raises Target
Guggenheim analyst Vamil Divan maintains a Buy rating on Travere Therapeutics and raises the price target to $65
EQUITY | Jun 25, 2026, 02:19 PM UTC
M
TVTX: Guggenheim Raises PT
Guggenheim analyst Vamil Divan raises price target on Travere Therapeutics to $65 and keeps Buy rating ahead of Q2 earnings
EQUITY | Jun 25, 2026, 12:13 PM UTC
M
TVTX: Wedbush Raises Target
Wedbush maintains Outperform on Travere Therapeutics and raises price target to $61
EQUITY | Jun 22, 2026, 01:00 PM UTC